These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 1404229

  • 1. Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3- hydroxypropoxy)-phenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran, a potent orally active platelet-activating factor (PAF) antagonist and its water-soluble prodrug phosphate ester.
    Girotra NN, Biftu T, Ponpipom MM, Acton JJ, Alberts AW, Bach TN, Ball RG, Bugianesi RL, Parsons WH, Chabala JC.
    J Med Chem; 1992 Sep 18; 35(19):3474-82. PubMed ID: 1404229
    [Abstract] [Full Text] [Related]

  • 2. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Szalkowski DM, MacIntyre DE, Bach TJ, Luell S, Meuer R, Sahoo SP, Alberts AW, Chabala JC.
    J Lipid Mediat; 1993 Jun 18; 7(2):115-34. PubMed ID: 8400114
    [Abstract] [Full Text] [Related]

  • 3. (+/-)-trans-2-(3-Methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5- trimethoxyphenyl)tetrahydrofuran (L-659,989), a novel, potent PAF receptor antagonist.
    Ponpipom MM, Hwang SB, Doebber TW, Acton JJ, Alberts AW, Biftu T, Brooker DR, Bugianesi RL, Chabala JC, Gamble NL.
    Biochem Biophys Res Commun; 1988 Feb 15; 150(3):1213-20. PubMed ID: 2829894
    [Abstract] [Full Text] [Related]

  • 4. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Alberts AW, Bugianesi RL, Chabala JC, Ponpipom MM.
    J Pharmacol Exp Ther; 1988 Aug 15; 246(2):534-41. PubMed ID: 2841449
    [Abstract] [Full Text] [Related]

  • 5. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM, Bernat A, Valette G, Gigo V, Lale A, LaPlace MC, Lespy L, Savi P, Maffrand JP, Le Fur G.
    J Pharmacol Exp Ther; 1991 Oct 15; 259(1):44-51. PubMed ID: 1656029
    [Abstract] [Full Text] [Related]

  • 6. Structure-activity relationships in platelet-activating factor (PAF antagonists). 6. Synthesis and in vitro antagonistic activities of 2-substituted 5-oxotetrahydrofurans.
    Favre E, Heymans F, Redeuilh C, Batt JP, Massicot F, Blavet N, Braquet P, Godfroid JJ.
    J Lipid Mediat; 1992 Feb 15; 5(1):23-40. PubMed ID: 1449553
    [Abstract] [Full Text] [Related]

  • 7. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
    Terashita Z, Kawamura M, Takatani M, Tsushima S, Imura Y, Nishikawa K.
    J Pharmacol Exp Ther; 1992 Feb 15; 260(2):748-55. PubMed ID: 1738121
    [Abstract] [Full Text] [Related]

  • 8. Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist.
    Albert DH, Conway RG, Magoc TJ, Tapang P, Rhein DA, Luo G, Holms JH, Davidsen SK, Summers JB, Carter GW.
    J Pharmacol Exp Ther; 1996 Jun 15; 277(3):1595-606. PubMed ID: 8667228
    [Abstract] [Full Text] [Related]

  • 9. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J.
    J Pharmacol Exp Ther; 1997 Jan 15; 280(1):114-21. PubMed ID: 8996188
    [Abstract] [Full Text] [Related]

  • 10. trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor.
    Hwang SB, Lam MH, Biftu T, Beattie TR, Shen TY.
    J Biol Chem; 1985 Dec 15; 260(29):15639-45. PubMed ID: 2999126
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of the platelet activating factor (PAF)-induced in vivo responses in rats by trans-2,5-(3,4,5-trimethoxyphenyl) tetrahydrofuran (L-652,731), a PAF receptor antagonist.
    Wu MS, Biftu T, Doebber TW.
    J Pharmacol Exp Ther; 1986 Dec 15; 239(3):841-5. PubMed ID: 3795043
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
    Tsunoda H, Sakuma Y, Harada K, Muramoto K, Katayama S, Horie T, Shimomura N, Clark R, Miyazawa S, Okano K.
    Arzneimittelforschung; 1990 Nov 15; 40(11):1201-5. PubMed ID: 2085331
    [Abstract] [Full Text] [Related]

  • 13. Disubstituted tetrahydrofurans and dioxolanes and PAF antagonists.
    Bartrolí J, Carceller E, Merlos M, García-Rafanell J, Forn J.
    J Med Chem; 1991 Jan 15; 34(1):373-86. PubMed ID: 1992139
    [Abstract] [Full Text] [Related]

  • 14. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
    Kagoshima M, Tomomatsu N, Iwahisa Y, Yamaguchi S, Kawakami Y, Terasawa M.
    Pharmacology; 1997 May 15; 54(5):261-70. PubMed ID: 9380772
    [Abstract] [Full Text] [Related]

  • 15. 4-substituted 2-alkoxytetrahydrofurans as potent and long-lasting PAF antagonists.
    Carceller E, Merlos M, Giral M, Bartrolí J, García-Rafanell J, Forn J.
    J Med Chem; 1992 Feb 21; 35(4):676-83. PubMed ID: 1542094
    [Abstract] [Full Text] [Related]

  • 16. 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
    Cooper K, Fray MJ, Parry MJ, Richardson K, Steele J.
    J Med Chem; 1992 Aug 21; 35(17):3115-29. PubMed ID: 1507200
    [Abstract] [Full Text] [Related]

  • 17. Conformation and activity of tetrahydrofuran lignans and analogues as specific platelet activating factor antagonists.
    Biftu T, Gamble NF, Doebber T, Hwang SB, Shen TY, Snyder J, Springer JP, Stevenson R.
    J Med Chem; 1986 Oct 21; 29(10):1917-21. PubMed ID: 3020247
    [Abstract] [Full Text] [Related]

  • 18. Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist.
    Albert DH, Magoc TJ, Menacherry SD, Morgan DW, Sun E, Reyes AE, Kleinert HD, Carter GW, Summers JB.
    Inflamm Res; 1997 Jul 21; 46(7):272-7. PubMed ID: 9266276
    [Abstract] [Full Text] [Related]

  • 19. Determination of enantiomeric concentrations of a 2,5-diaryltetrahydrofuran (L-668,750), a platelet-activating factor receptor antagonist, in rat plasma using a chiral alpha 1-acid glycoprotein high-performance liquid chromatographic column.
    Alvaro RF, Rosegay A, Chiu SH.
    J Chromatogr; 1992 Jul 24; 578(2):327-32. PubMed ID: 1328270
    [Abstract] [Full Text] [Related]

  • 20. Sch 37370: a potent, orally active, dual antagonist of platelet-activating factor and histamine.
    Billah MM, Chapman RW, Egan RW, Gilchrest H, Piwinski JJ, Sherwood J, Siegel MI, West RE, Kreutner W.
    J Pharmacol Exp Ther; 1990 Mar 24; 252(3):1090-6. PubMed ID: 2319461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.